MILESTONE MEDICAL - Announcement of Successful Economic Study Comparing Total Costs of CompuFlo® Epidural System Versus Traditional Epidural Loss of Resistance Technique

KOMISJA NADZORU FINANSOWEGO

Raport bieżący nr 13 / 2020

Data sporządzenia: 2020-04-17

Skrócona nazwa emitenta

MILESTONE MEDICAL

Temat

Announcement of Successful Economic Study Comparing Total Costs of CompuFlo® Epidural System Versus Traditional Epidural Loss of Resistance Technique

Podstawa prawna

Art. 17 ust. 1 MAR - informacje poufne.

Treść raportu:

The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”) today reported a study titled: “Cost Effectiveness Analysis of Two Labor Epidural Analgesia Techniques; Real-Time Pressure Sensing Technology and Traditional Technique,” has been electronically presented for the American Society of Regional Anesthesia and Pain Medicine (ASRA). The poster was originally planned for live presentation at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting, which was canceled due to the COVID-19 pandemic. The scientific session and poster sessions were placed on-line so that the researchers could present their findings. Further details of the study will be forthcoming and will be submitted for publication in a premier peer-reviewed medical journal. The aim of the study was to evaluate the cost-effectiveness of the CompuFlo® Epidural System with DPS Dynamic Pressure Sensing technology® versus the traditional loss of resistance technique within the labor and delivery setting in medical centers. The data was presented by the primary investigator, Professor Rovnat Babazade, MD, University of Texas Medical Branch at Galveston, Department of Anesthesiology, who concluded that this is the first study in the literature that reports cost of the real-time pressure sensing technique and the traditional LOR technique in parturients requesting labor epidural analgesia. Compared to the traditional LOR technique, real-time pressure sensing technology costs about 504 dollars less per hospital stay on average. The study included the review of some 4,483 deliveries and ensuing complications from performing the epidural procedure, which included accidental dural puncture, post-dural puncture headache, interventional epidural blood patch and need for extended hospital stays and readmissions. A cost effectiveness analysis was estimated for the total cost of the hospital stay for delivery and readmission for these procedures. A cost reduction when using CompuFlo® Epidural System was demonstrated by the analysis conducted in this study. The Board of Directors of the Issuer announces that this is the first major study to clearly validate the cost benefits of the CompuFlo® Epidural System. In addition to the important safety advantages of our instrument, this study compared the rate of accidental dural puncture, a common complication of traditional epidural anesthesia. Accidental dural puncture is a significant contributor to increased hospital costs, prolonged hospitalization and the need for further treatment and interventions. This study, which has been submitted for publication in a leading peer-reviewed medical journal, provides valuable third-party validation of the cost benefits of our instrument. The Board of Directors of the Company believes this study will be an important tool as it presents the value proposition of the instrument to hospitals across the country.

MESSAGE (ENGLISH VERSION)

MILESTONE MEDICAL INC

(pełna nazwa emitenta)

MILESTONE MEDICAL

(skrócona nazwa emitenta) (sektor wg. klasyfikacji GPW w W-wie)

NJ 07039 .

(kod pocztowy) (miejscowość)

South Orange Avenue Livingston 220

(ulica) (numer)

[phone] [phone]

(telefon) (fax)

(e-mail) (www)

27-5484393

(NIP) (REGON)

PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ

Data Imię i Nazwisko Stanowisko/Funkcja Podpis

2020-04-17 Joseph D'Agostino Chief Financial Officer Joseph D'Agostino